> >Register Now <<

Speaker: Joseph J. Taylor, MD, PhD

Neuroimaging is common in psychiatric research but rarely applied in psychiatric practice, even for brain stimulation treatments like transcranial magnetic stimulation (TMS). Recently, neuroimaging was used to target TMS during a condensed or “accelerated” treatment protocol. Known as Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), this intervention resulted in rapid and substantial antidepressant benefits. However, it remains unclear if neuroimaging is necessary for the rapid and substantial antidepressant benefits of accelerated TMS. This question is important to answer because neuroimaging adds cost and complexity to TMS. Here, we will present data from the first head-to-head trial of accelerated TMS with and without imaging guidance for treatment-resistant depression.

Key learning objectives include:

• Describe the development of accelerated TMS.
• Outline the five ways that the Cole et al protocol (branded SAINT) differs from conventional iTMS.
• Summarize the results of this trial comparing imaging-versus scalp-based targeting of accelerated TMS.

One CME credit is available.  CE Language

Take advantage of our live Q&A session at the conclusion of the webinar.

*Registered attendees will receive access to the on-demand video recording by Friday, March 6, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.

When:

USA - March 3, 2026 at 8:00pm ET | 5:00pm PT
UK- March 4, 2026 at 1:00am GMT
Australia- March 4, 2026 at 12:00pm AEDT

Cost:

Member: $25
Trainee Member: FREE
Non-Member: $50

> >Register Now <<

About the Speaker

Joseph J. Taylor, MD, PhD
Dr. Taylor is an Assistant Professor of Psychiatry at Harvard Medical School. At Brigham and Women’s Hospital, he is the Medical Director of TMS and the Director of Clinical Trials in the Center for Brain Circuit Therapeutics, the Director of the Interventional Psychiatry Research Program, and the Associate Program Director and Research Track Co-Director of the Psychiatry Residency Program. Dr. Taylor’s has expertise in interventional psychiatry, an emerging subspecialty in which procedural treatments are used for psychiatric illnesses that have not improved with routine psychotherapy and medications. Most of his research focuses on deriving and testing brain circuit targets for brain stimulation or neurosurgical ablation. Throughout his career, Dr. Taylor has received funding from the Howard Hughes Medical Institute, the National institutes of Health, the Sidney R. Baer, Jr. Foundation, the Baszucki Group, the Brain and Behavioral Research Foundation, Mass General Brigham, and Harvard Medical School.